LeMaitre Vascular, Inc. (NASDAQ:LMAT), is not the largest company out there, but it saw a decent share price growth of 16% on the NASDAQGM over the last few months. The company's trading levels have approached the yearly peak, following the recent bounce in the share price. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s examine LeMaitre Vascular’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

See our latest analysis for LeMaitre Vascular

What's The Opportunity In LeMaitre Vascular?

According to our valuation model, LeMaitre Vascular seems to be fairly priced at around 1.1% below our intrinsic value, which means if you buy LeMaitre Vascular today, you’d be paying a fair price for it. And if you believe the company’s true value is $90.66, then there isn’t much room for the share price grow beyond what it’s currently trading. What's more, LeMaitre Vascular’s share price may be more stable over time (relative to the market), as indicated by its low beta.

Can we expect growth from LeMaitre Vascular?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 49% over the next couple of years, the future seems bright for LeMaitre Vascular. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? LMAT’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping an eye on LMAT, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.